Expression of CD8 can act either as a prognostic or a predictive factor of clinical outcome: in NSCLC patients not treated by immunotherapy, high CD8A expression is associated with longer OS, while in NSCLC patients treated with anti PD1, high CD8 expression is associated with longer PFS (145). This evidence concerns the gene CD8A and non-small cell lung carcinoma.